Rhbinvest.com.hk

Hong Kong Results Review
FY15: beat consensus but missed ours Industrial Misc. Manufacturer Neutral (Maintained)
Tianneng Power
Decent Outlook Priced In
Bloomberg Ticker: In the post results meeting, management highlighted the aggressive Share Data
lithium batteries capacity expansion plan and the auto industry's Avg Daily Turnover (HKD/USD)
electrification trend. Many large automakers in China/overseas are liaising 52-wk Price low/high (HKD)
with Tianneng for potential battery supply. We tweak our FY15 earnings
for missing our estimates and maintain NEUTRAL, with a HKD5.72 TP
Free Float (%)
(from HKD5.20, 9% downside) based on 1.25x FY16F P/BV. We believe the Shares outstanding (m)
recent rally already priced in the strong lithium growth story, the Estimated Return
continuous cost reductions and one-off higher dividend payout for FY15.
Shareholders (%)
The future growth driver.
Tianneng Power (Tianneng) plans to add 80% Zhang Tianren
more lithium battery capacity pa in FY16-17F (end-FY15: 1,250 megawatt hour UBS AG or MWh). It has a top research & development (R&D) team and can produce high-quality batteries that have high consistency and power competiveness, and fast recharging. Many automakers are planning to enter the electric vehicle Share Performance (%) (EV) market and are likely to outsource their battery production to makers like Tianneng. Lithium batteries accounted for 3% of FY15 revenue and its contribution is likely to rise to 4%/6% in FY16-17F respectively, in our view. E-bike battery prices stable. Tianneng slightly lowered ASP in 2H15 to
Source: Bloomberg stimulate sales and expand market share. Thus, 2H15 gross margins fell HoH. Looking ahead, the ASP is likely to be stable, given that Tianneng is satisfied with its market share. ASP hiked YoY in Jan-Feb 2016, according to the firm. Tianneng Power (819 HK)
Relative to Hang Seng Index (RHS) Cost controls to continue in FY16. FY16 capex is CNY600m-800m, of which
70% is to be allocated for lithium batteries. Tianneng also said that the administrative expenses/revenue ratio is likely to fall this year on better management and larger operating scale. Risk: The resumption of an e-bike lead acid battery price war.
FY15 Results: beat consensus but miss our estimates Comments
Lead-acid battery growth Higher market share on Slightly lower prices Source: Bloomberg Operating profit SG&A well managed Core rolling P/E (x) Recurring earnings Source: Company data, RHB Maintain NEUTRAL with a higher HKD5.72 TP (from HKD5.20). We raise our
TP by 10% to HKD5.72 by raising target P/BV to 1.25x from 1.10x, which is its +0.5SD of the past 5-year P/BV. This is given the firm's improving outlook. As our new TP is 8% below the current share price, we believe its strong recovery is priced in. We stick with P/BV as our valuation methodology (as opposed to Source: Bloomberg P/E), given Tianneng's highly volatile earnings history including losses. Forecasts and Valuations
Total turnover (CNYm) Reported net profit (CNYm) Recurring net profit (CNYm) Recurring net profit growth (%) Recurring EPS (CNY) Recurring P/E (x) Dividend Yield (%) Return on average equity (%) Net debt to equity (%) Our vs consensus EPS (adjusted) (%) Source: Company data, RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Financial Exhibits

Profit & Loss (CNYm)
Cash flow (CNYm)
( 268) 789
( 12,780) ( 15,376) ( 16,325) ( 17,811) ( 18,965) Depreciation & amortisation Gross profit
Change in working capital Gen & admin expenses ( 652) ( 598) ( 648) ( 708) ( 755) Other operating cash flow ( 870) ( 301) 69 ( 123) ( 151) ( 164) ( 179) ( 191) Operating cash flow
Other operating costs ( 756) ( 890) ( 941) ( 1,028) ( 1,096) ( 196) ( 182) ( 159) ( 135) ( 125) ( 268) 789
Cash flow from operations
Depreciation of fixed assets ( 188) ( 220) ( 311) ( 270) ( 302) ( 729) ( 751) ( 422) ( 700) ( 700) Amortisation of intangible assets Other investing cash flow ( 268) 789
Cash flow from investing activities
( 487) ( 829) ( 895) ( 741) ( 741)
Other recurring income ( 206) ( 163) ( 135) ( 125) ( 125) Other non-recurring income Other financing cash flow ( 407) 746
Cash flow from financing activities
( 320) 735
( 1,416) ( 602) ( 298)
( 118) ( 225) ( 251) ( 301) Cash at beginning of period Minority interests Total cash generated
( 302) ( 545) ( 53)
Reported net profit
( 305) 611
Implied cash at end of period
Recurring net profit
( 250) 649
,167 Source: Company data, RHB
Source: Company data, RHB Balance Sheet (CNYm)
Key Ratios
Total cash and equivalents Revenue growth (%) Operating profit growth (%) Accounts receivable Recurring net profit growth (%) Other current assets Recurrent EPS growth (%) Total current assets
Tangible fixed assets Operating EBITDA margin (%) Intangible assets Operating margin (%) Total other assets Recurring net profit margin (%) Total non-current assets Return on average assets (%) Total assets
Return on average equity (%) Net debt to equity (%) Interest cover (x) Other current liabilities Capex/Free cash flow (%) Total current liabilities
Total long-term debt Other liabilities Dividend payout ratio (%) Total non-current liabilities
Free cash flow per share (CNY) 0.26 Total liabilities
Source: Company data, RHB Retained earnings reserve Minority interests Total equity
Total liabilities & equity
Source: Company data, RHB Revenue growth vs Recurring net profit growth
EBITDA margin vs Net profit margin
Recurring net profit growth Operating EBITDA margin Net profit margin Source: Company data, RHB Source: Company data, RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer FY15 Results Review
FY15 results beat consensus but missed ours. Tianneng's FY15 recurring net profit
turned around from a loss to CNY649m, below our estimates by 11% but better than
Bloomberg consensus by 15%. 2H15 recurring earnings turned around YoY to CNY375m.
FY15 revenue rose 27%YoY, ie above our and consensus estimates by 8% and 6%
respectively. 2H15 topline rose 38%YoY. Lead-acid battery revenue increased 32%YoY in
2H15, ie higher than had been expected, while lithium battery sales surged 288%YoY.
This was slightly below expectations.
Gross margins squeezed in 2H15. Tianneng booked gross margins of 13.6% in FY15,
significantly better than FY14's 9%. However, it fell to 13% in 2H15 vs 14.5% in 1H15.
Sales, general & administrative (SG&A) expenses well managed. Opex/revenue ratio
fell to 9.2% in FY15. By comparison, this stood at 10.9% in FY14, 9.7% in 1H15 and 8.9%
in 2H15. In particular, SG&A expenses declined despite the higher revenue. Meanwhile,
R&D expenses surged 40%YoY, mainly on the lithium battery segment.
Finance costs declined. Finance costs declined by as much as 20%YoY, mainly due to a
debt repayment of CNY1.4bn made in FY15. Tianneng's total debt fell by 40%YoY to
CNY2.2bn in FY15, while gearing fell to only 1%. By comparison, it was 65% as at end-
FY14 and 30% at end-1H15.).
Effective tax rate also fell. Tianneng's effective tax rate lowered to 15.8% in FY15 vs
28% in FY14. This was because some of its subsidiaries were recognised as high-tech
companies, which enjoy a lower tax rate for a certain period.
Final dividend of 31.8 cents per share (nil in 2014). Implied dividend yield is 5.6%.
Payout ratio was 50%, which was above the historical payout of about 30% since
Tianneng's IPO in 2007 (excluding FY14). The higher payout this year was to celebrate
the company's 30th anniversary, according to our discussion with management. Future
payouts, it guided, would be consistent with historical levels.
Decent working capital controls. Inventory days fell to 35 (FY14: 49) and payable days
surged to 85 (FY14: 61). Accounts receivables (AR) days uplifted to normal levels of 42
(FY14: 38). As a result, Tianneng enjoyed operating inflow of as much as CNY2bn, ie
capable of repaying its CNY1.4bn debt to reduce finance expenses and boost earnings.
See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Figure 1: Tianneng's FY15 results (CNYm)
Pure electric car Lead-acid battery ( 12,780) ( 15,376) ( 13,812) 1 ( 6,440) ( 8,936) ( 7,372) 2 Gross profit
Selling & distribution expenses ( 652) ( 598) ( 611) ( 2.0) ( 273) ( 325) ( 337) ( 3.7) Administrative expenses ( 352) ( 324) ( 347) ( 6.5) ( 151) ( 173) ( 196) ( 11.6) Other operating expenses ( 1,531) ( 1,639) ( 1,630) 0
( 727) ( 912) ( 903) 1
Opex as % of revenue ( 201) 909
( 206) ( 163) ( 211) ( 22.5) ( 86) ( 77) ( 124) ( 38.2) ( 407) 746
( 118) ( 200) ( 41.1) ( 68) ( 50) ( 132) ( 62.2) Effective tax rate Net profit - reported
( 305) 611
Net profit - recurring
( 250) 649
Source: RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Figure 2: Changes to our forecasts (CNYm)
Pure electric car Lead-acid battery ( 16,325) ( 15,171) 7 ( 17,811) ( 16,820) 5 Gross profit
Selling & distribution expenses ( 648) ( 691) ( 6.2) ( 708) ( 767) ( 7.7) ( 755) Administrative expenses ( 328) ( 392) ( 16.4) ( 358) ( 436) ( 17.7) ( 382) Other operating expenses ( 179) ( 182) ( 1.5) ( 191) ( 1,754) ( 1,846) ( 5.0) ( 1,916) ( 2,049) ( 6.5) ( 2,042)
Opex as % of revenue ( 135) ( 189) ( 28.6) ( 125) ( 189) ( 33.9) ( 125) ( 225) ( 397) ( 43.4) ( 251) ( 448) ( 44.1) ( 301) Effective tax rate Net profit - reported
Net profit - recurring
Source: RHB Figure 3: Key assumptions
E-bike battery sales volume growth Tricycle battery sales volume growth Pure eletronic car battery sales volume growth E-bike battery ASP change Lithium battery revenue growth Source: RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Figure 4: Tianneng's detailed P&L statement (CNYm)
Pure electric car Lead-acid battery ( 12,231) ( 12,780) ( 15,376) ( 16,325) ( 17,811) ( 18,965) Gross profit
Other operating expenses ( 105) ( 123) ( 151) ( 164) ( 179) ( 191) Selling & distribution expenses ( 413) ( 652) ( 598) ( 648) ( 708) ( 755) Administrative expenses ( 367) ( 352) ( 324) ( 328) ( 358) ( 382) ( 355) ( 405) ( 566) ( 613) ( 670) ( 714) ( 1,240) ( 1,531) ( 1,639) ( 1,754) ( 1,916) ( 2,042)
Opex as % of revenue ( 201) 909
( 144) ( 206) ( 163) ( 135) ( 125) ( 125) Share of associates' profits ( 407) 746
( 118) ( 225) ( 251) ( 301) Effective tax rate Net profit - reported
( 305) 611
Net profit - recurring
( 250) 649
Source: RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Figure 5: Tianneng's 5-year forward P/BV band
Source: Bloomberg, RHB Figure 6: Peers comparison I
Price (USDm) (USDm) 2014 (x) FY15 (x) FY16 (x)
YoY% Cagr (%) PEG (x) FY14 (%) FY15 (%) FY15 (x)
HK-listed battery makers
Overseas listed battery makers
China BAK Battery Note: Prices as at 21 Mar 2016 Source: Bloomberg, RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer Figure 7: Peers comparison II
Rev Hist Rev FY1 NP Hist NP FY1 margin
Beta (USDm) (USDm) (USDm) (USDm) FY14 (%) FY14 (%) FY15 (%) FY14 (%) FY15 (%) FY16 (%) FY14 (%) FY15 (%)
HK-listed battery makers
Overseas listed battery makers
China BAK Battery Note: Prices as at 21 Mar 2016 Source: Bloomberg, RHB See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer SWOT Analysis

 A key player in the lead acid battery industry, with an estimated 35% share of the electric bike market in from Chaowei Power  E-bike market has been developing for long time and is entering its mature stage  Lithium battery is a new growth driver Government's concerns on air pollution have resulted in more favourable policies on the electric vehicles segment  More stringent environmental protection  High original equipment manufacturer (OEM) proportion increases production costs lead acid batteries squeezing out smaller players Recommendation Chart
Target Price
Recommendations & Tar get Pri ce Source: RHB, Bloomberg Source: RHB, Bloomberg See important disclosures at the end of this report
Hong Kong Results Review Industrial Misc. Manufacturer RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months
Trading Buy: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain
Neutral: Share price may fall within the range of +/- 10% over the next 12 months
Take Profit: Target price has been attained. Look to accumulate at lower levels
Sell: Share price may fall by more than 10% over the next 12 months
Not Rated: Stock is not within regular research coverage
Investment Research Disclaimers
RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments. This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws. All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed. Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors. This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report. This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this Hong Kong Results Review Industrial Misc. Manufacturer report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward- looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events. The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk. This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content. The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover. RHB and/or its affiliates and/or their directors, officers, associates, connected parties and/or employees, may have, or have had, interests in the securities or qualified holdings, in subject company(ies) mentioned in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, RHB and/or its affiliates may have, or have had, business relationships with the subject company(ies) mentioned in this report and may from time to time seek to provide investment banking or other services to the subject company(ies) referred to in this research report. As a result, investors should be aware that a conflict of interest may exist. The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect. The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors. The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this RESTRICTIONS ON DISTRIBUTION
Malaysia
This report is issued and distributed in Malaysia by RHB Research Institute Sdn Bhd. The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHB Research Institute Sdn Bhd has no obligation to update its opinion or the information in this report. Thailand
This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies. Hong Kong Results Review Industrial Misc. Manufacturer Indonesia
This report is issued and distributed in Indonesia by PT RHB Securities Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations. Singapore
This report is issued and distributed in Singapore by RHB Research Institute Singapore Pte Ltd and it may only be distributed in Singapore to accredited investors, expert investors and institutional investors as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. By virtue of distribution to these categories of investors, RHB Research Institute Singapore Pte Ltd and its representatives are not required to comply with Section 36 of the Financial Advisers Act (Chapter 110) (Section 36 relates to disclosure of RHB Research Institute Singapore Pte Ltd 's interest and/or its representative's interest in securities). Recipients of this report in Singapore may contact RHB Research Institute Singapore Pte Ltd in respect of any matter arising from or in connection with the report. Hong Kong
This report is issued and distributed in Hong Kong by RHB Securities Hong Kong Limited (興業僑豐證券有限公司) (CE No.: ADU220) ("RHBSHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) regulated activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact RHB Securities Hong Kong Limited. United States
This report was prepared by RHB and is being distributed solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the
requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act"). RHB is not registered as a broker- dealer in the United States and does not offer brokerage services to U.S. persons. Any order for the purchase or sale of the securities discussed herein that are listed on Bursa Malaysia Securities Berhad must be placed with and through Auerbach Grayson ("AG"). Any order for the purchase or sale of all other securities discussed herein must be placed with and through such other registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of Auerbach Grayson AG or such other registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States. OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST
Malaysia
RHB does not have qualified shareholding (1% or more) in the subject company (ies) covered in this report except for: RHB and/or its subsidiaries are not liquidity providers or market makers for the subject company (ies) covered in this report except for: RHB and/or its subsidiaries have not participated as a syndicate member in share offerings and/or bond issues in securities covered in this report in the last 12 months except for: RHB has not provided investment banking services to the company/companies covered in this report in the last 12 months except for: Hong Kong Results Review Industrial Misc. Manufacturer Thailand
RHB Securities (Thailand) PCL and/or its directors, officers, associates, connected parties and/or employees, may have, or have had, interests and/or commitments in the securities in subject company(ies) mentioned in this report or any securities related thereto. Further, RHB Securities (Thailand) PCL may have, or have had, business relationships with the subject company(ies) mentioned in this report. As a result, investors should exercise their own judgment carefully before making any investment decisions. Indonesia
PT RHB Securities Indonesia is not affiliated with the subject company(ies) covered in this report both directly or indirectly as per the definitions of affiliation above. Pursuant to the Capital Market Law (Law Number 8 Year 1995) and the supporting regulations thereof, what constitutes as affiliated parties are as follows: Familial relationship due to marriage or blood up to the second degree, both horizontally or vertically; Affiliation between parties to the employees, Directors or Commissioners of the parties concerned; Affiliation between 2 companies whereby one or more member of the Board of Directors or the Commissioners are the same; Affiliation between the Company and the parties, both directly or indirectly, controlling or being controlled by the Company; Affiliation between 2 companies which are controlled, directly or indirectly, by the same party; or Affiliation between the Company and the main Shareholders. PT RHB Securities Indonesia is not an insider as defined in the Capital Market Law and the information contained in this report is not considered as insider information prohibited by law. a commissioner, director or employee of an Issuer or Public Company; a substantial shareholder of an Issuer or Public Company; an individual, who because of his position or profession, or because of a business relationship with an Issuer or Public Company, has access to inside information; and an individual who within the last six months was a Person defined in letters a, b or c, above. Singapore
RHB Research Institute Singapore Pte Ltd and/or its subsidiaries and/or associated companies do not make a market in any securities covered in this report, except for: The staff of RHB Research Institute Singapore Pte Ltd and its subsidiaries and/or its associated companies do not serve on any board or trustee positions of any issuer whose securities are covered in this report, except for: RHB Research Institute Singapore Pte Ltd and/or its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer of the securities covered in this report or any other relationship (including a shareholding of 1% or more in the securities covered in this report) that may create a potential conflict of interest, except for: Hong Kong
RHBSHK or any of its group companies may have financial interests in in relation to an issuer or a new listing applicant (as the case may be) the securities in respect of which are reviewed in the report, and such interests aggregate to an amount equal to or more than (a) 1% of the subject company's market capitalization (in the case of an issuer as defined under paragraph 16 of the Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the "Code of Conduct"); and/or (b) an amount equal to or more than 1% of the subject company's issued share capital, or issued units, as applicable (in the case of a new listing applicant as defined in the Code of Conduct). Further, the analysts named in this report or their associates may have financial interests in relation to an issuer or a new listing applicant (as the case may be) in the securities which are reviewed in the report. Hong Kong Results Review Industrial Misc. Manufacturer RHBSHK or any of its group companies may make a market in the securities covered by this report. RHBSHK or any of its group companies may have analysts or their associates, individual(s) employed by or associated with RHBSHK or any of its group companies serving as an officer of the company or any of the companies covered by this report. RHBSHK or any of its group companies may have received compensation or a mandate for investment banking services to the company or any of the companies covered by this report within the past 12 months. Note: The reference to "group companies" above refers to a group company of RHBSHK that carries on a business in Hong Kong in (a) investment banking; (b) proprietary trading or market making; or (c) agency broking, in relation to securities listed or traded on The Stock Exchange of Hong Kong Limited.


Kuala Lumpur
Hong Kong
Singapore
RHB Research Institute Sdn Bhd
RHB Securities Hong Kong Ltd.
RHB Research Institute Singapore
Level 11, Tower One, RHB Centre World-Wide House 19 Des Voeux Road #09-08 Ocean Financial Centre Central, Hong Kong Singapore 049315 Tel : +(60) 3 9280 2185 Tel : +(852) 2525 1118 Tel : +(65) 6533 1818 Fax : +(60) 3 9284 8693 Fax : +(852) 2810 0908 Fax : +(65) 6532 6211 Shanghai
PT RHB Securities Indonesia
RHB (China) Investment Advisory Co. Ltd.
RHB Securities (Thailand) PCL
Wisma Mulia, 20th Floor Suite 4005, CITIC Square 10th Floor, Sathorn Square Office Tower Jl. Jenderal Gatot Subroto No. 42 1168 Nanjing West Road 98, North Sathorn Road, Silom Jakarta 12710, Indonesia Bangrak, Bangkok 10500 Tel : +(6221) 2783 0888 Fax : +(6221) 2783 0777 Tel : +(8621) 6288 9611 Tel: +(66) 2 862 9999 Fax : +(8621) 6288 9633 Fax : +(66) 2 862 9799

Source: https://www.rhbinvest.com.hk/CMSPages/GetFile.aspx?guid=14c3ae3e-9cff-4e36-805a-4e6ce2d28e44

Microsoft word - gutachten.doc

Institut für Baubiologie Rosenheim GmbH aufgrund des Prüfsiegels „Geprüft und Empfohlen vom IBR" für die Produkte Schöck ComBAR® Antragsteller: Schöck Bauteile GmbH Vimbucher www.schoeck.de Proben: am 02.03.2011 beim Auftraggeber durch das IBR entnommen. Mitarbeiter des IBR Dieses Gutachten darf nur ungekürzt und unverändert vervielfältigt und veröffentlicht werden.

Microsoft word - mimeattach5370.bin

ARCH-Vet 2013 Published by Federal Department of Home Affairs FDHA Federal Food Safety and Veterinary Office FSVO Schwarzenburgstrasse 155 3003 Bern, Switzerland Authors Sabina Büttner Federal Food Safety and Veterinary Office Veterinary Medicinal Products and Antibiotics sabina.buettner@blv.admin.ch Marion Mehmann Federal Food Safety and Veterinary Office Veterinary Medicinal Products and Antibiotics marion.mehmann@blv.admin.ch Cedric Müntener Institute of Pharmacology and Toxicology University of Zurich cedric.muentener@vetpharm.uzh.ch Kay Torriani Federal Food Safety and Veterinary Office Veterinary Medicinal Products and Antibiotics kay.torriani@blv.admin.chmailto: Gudrun Overesch Centre for Zoonoses, Bacterial Animal Diseases and Antibiotic Resistance (ZOBA) University of Bern Institute of Veterinary Bacteriology gudrun.overesch@vetsuisse.unibe.ch

Copyright © 2008-2016 No Medical Care